X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Belharra will be responsible for discovery and early preclinical development of small molecules against Genentech’s designated targets, while Genentech will be responsible for late preclinical, clinical, and regulatory development, and commercialization.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $2,080.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration January 04, 2023
Details:
Belharra’s integrated chemoproteomic-based drug discovery engine addresses the limitations of traditional screening approaches through a proprietary library of photoaffinity-based chemical probes that explore protein-ligand interactions in the native environment of the cell.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
